Ratings PetMed Express, Inc.

Equities

PETS

US7163821066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.02 ^USD	-0.74%		-2.19%	-46.83%

Apr. 15	Earnings Flash (PETS) PETMED EXPRESS Posts Q3 Revenue $65.3M	MT
Apr. 15	PetMed Express, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company is in a robust financial situation considering its net cash and margin position.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.12 for the 2024 fiscal year.
The company appears to be poorly valued given its net asset value.
This company will be of major interest to investors in search of a high dividend stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
PETMED EXPRESS, INC.	-46.83%	81.99M		C
RAIA DROGASIL S.A.	-12.86%	8.57B		B
AIN HOLDINGS INC.	+32.95%	1.32B		-
QOL HOLDINGS CO., LTD.	+6.76%	419M		-
NIHON CHOUZAI CO.,LTD.	+5.93%	282M		-
SALUS, LJUBLJANA, D. D.	+10.56%	224M	-	-
GREEN CROSS HEALTH LIMITED	-8.26%	85.07M	-	-
MEDICAL IKKOU GROUP CO.,LTD.	+20.94%	59.57M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes